BR112022025198A2 - Formas sólidas do inibidor de apol1 e uso das mesmas - Google Patents

Formas sólidas do inibidor de apol1 e uso das mesmas

Info

Publication number
BR112022025198A2
BR112022025198A2 BR112022025198A BR112022025198A BR112022025198A2 BR 112022025198 A2 BR112022025198 A2 BR 112022025198A2 BR 112022025198 A BR112022025198 A BR 112022025198A BR 112022025198 A BR112022025198 A BR 112022025198A BR 112022025198 A2 BR112022025198 A2 BR 112022025198A2
Authority
BR
Brazil
Prior art keywords
apol1
inhibitor
solid forms
methods
ethanol solvate
Prior art date
Application number
BR112022025198A
Other languages
English (en)
Inventor
James Gagnon Kevin
Li Jicong
Medek Ales
Raphael Minchom Jack
Shi Yi
Shrestha Muna
Witkos Faith
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR112022025198A2 publication Critical patent/BR112022025198A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ORMAS SÓLIDAS DO INIBIDOR DE APOL1 E MÉTODOS DE USO DAS MESMAS. A divulgação fornece novas formas de estado sólido do Composto I selecionadas dentre a Forma A de solvato de etanol, Forma B de solvato de etanol, Forma A de co-cristal de ácido cítrico e Forma B, composições compreendendo as mesmas, e métodos de produção e uso das mesmas, incluindo o uso no tratamento de doença renal mediada por APOL1. (I).
BR112022025198A 2020-06-12 2021-06-11 Formas sólidas do inibidor de apol1 e uso das mesmas BR112022025198A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038271P 2020-06-12 2020-06-12
PCT/US2021/036960 WO2021252863A1 (en) 2020-06-12 2021-06-11 Solid forms of apol1 inhibitor and using the same

Publications (1)

Publication Number Publication Date
BR112022025198A2 true BR112022025198A2 (pt) 2022-12-27

Family

ID=76744980

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025198A BR112022025198A2 (pt) 2020-06-12 2021-06-11 Formas sólidas do inibidor de apol1 e uso das mesmas

Country Status (12)

Country Link
US (1) US20230250087A1 (pt)
EP (1) EP4165036A1 (pt)
JP (1) JP2023530276A (pt)
KR (1) KR20230024330A (pt)
CN (1) CN115867543A (pt)
AU (1) AU2021289750A1 (pt)
BR (1) BR112022025198A2 (pt)
CA (1) CA3183591A1 (pt)
IL (1) IL298083A (pt)
MX (1) MX2022015766A (pt)
TW (1) TW202214601A (pt)
WO (1) WO2021252863A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105769XA (en) 2018-12-17 2021-07-29 Vertex Pharma Inhibitors of apol1 and methods of using same
CN116348447A (zh) 2020-01-29 2023-06-27 弗特克斯药品有限公司 Apol1的抑制剂及其使用其的方法
WO2021178768A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
AU2023208684A1 (en) 2022-01-18 2024-09-05 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
SG11202105769XA (en) * 2018-12-17 2021-07-29 Vertex Pharma Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
TW202214601A (zh) 2022-04-16
MX2022015766A (es) 2023-02-23
WO2021252863A1 (en) 2021-12-16
CN115867543A (zh) 2023-03-28
US20230250087A1 (en) 2023-08-10
KR20230024330A (ko) 2023-02-20
CA3183591A1 (en) 2021-12-16
AU2021289750A1 (en) 2023-02-02
IL298083A (en) 2023-01-01
EP4165036A1 (en) 2023-04-19
JP2023530276A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112022025198A2 (pt) Formas sólidas do inibidor de apol1 e uso das mesmas
CL2020002026A1 (es) Inhibidor de fap.
CL2021001561A1 (es) Inhibidores de apol1 y sus métodos de uso
EA202090419A1 (ru) Селективные ингибиторы инфламмасомы nlrp3
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
NO20064120L (no) 3-'4-heterocyklyl-1,2,3,-triazol-l-yll-N-aryl-benzamid er som inhibitorer av cytokinproduksjon for behandling av kroniske inflammatoriske sykdommer
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
UY38696A (es) Moduladores de alfa-1 antitripsina
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BRPI0507373A (pt) compostos e método de uso
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k
NI201100062A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
PA8559101A1 (es) Inhibidores del factor xa y de las otras proteasas de serina implicadas en la cascada de la coagulacion
DOP2010000103A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
DOP2020000083A (es) Compuesto de pirimidina como inhibidor de las janocinasas
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
DOP2012000312A (es) Triazolopiridinas sustituidas
ATE445389T1 (de) Liposomale glucocorticoide
ECSP21026485A (es) Piridazinonas y sus métodos de uso
CU20090216A7 (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ECSP22066085A (es) ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2